Peptide library / Digestive & weight / Petrelintide
Petrelintide
An investigational long-acting amylin analog from Zealand Pharma and Roche.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesitySmall human studies
How it is thought to work
Petrelintide mimics amylin to increase fullness, and aims to deliver weight loss with fewer gastrointestinal effects than GLP-1 drugs.
What the evidence shows
Early and mid-stage studies showed weight loss with a favorable tolerability profile, but data are limited to phase 1 and 2.
Safety and unknowns
Gastrointestinal effects were reported. Long-term safety is unknown.
Regulatory status
Not approved. Development continues in phase 2.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Plecanatide
FDA-approvedA 16 amino acid guanylate cyclase-C agonist for constipation and irritable bowel syndrome.
PN-943
In clinical trialsAn investigational oral peptide that stays in the gut and blocks immune cells from entering the bowel wall.
Pemvidutide
In clinical trialsAn investigational GLP-1 and glucagon dual agonist from Altimmune, aimed at fatty liver disease.
General information, not medical advice. Do not buy or inject unregulated peptides.